Related Funds
Fund Name | Location |
21st Century Internet Venture Partners | California, San Francisco, United States |
Aetna Ventures | Connecticut, Hartford, United States |
Almoayed Ventures | Bahrain, Capital Governorate, Manama |
AtlasInvest | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
Beijing Chunfeng Wanhua Touzi Guanli Youxian Gongsi | Beijing, China, Haidian |
Counterpart Advisors | California, Manhattan Beach, United States |
CREATE Partners | Cambridge, Cambridgeshire, United Kingdom |
Dimension | Japan, Tokyo |
Frontier Ventures | California, Cupertino, United States |
Fujisawa Investments for Entrepreneurship | Evanston, Illinois, United States |
Gallatin Point Capital | Connecticut, Greenwich, United States |
Kajima Corp | Chiba Prefecture, Japan, Tateyama |
lastminute.com group | Chiasso, Switzerland, Ticino |
Media Camp | Burbank, California, United States |
Middleton Enterprises | Newcastle upon Tyne, North East, United Kingdom |
Monestier Capital | - |
Nike Accelerator | Beaverton, Oregon, United States |
PS Alliance | Kyonggi-do, Seongnam, South Korea |
Quilvest Private Equity | France, Ile-de-France, Paris |
Uberis Capital | Cambodia, Phnom Penh |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Eubulus | $10M | 14 Oct 2021 | Jiaxing, Zhejiang, China | ||
Totient | $10M | 10 Sep 2020 | Cambridge, Massachusetts, United States | ||
Triumvira Immunologics | $55M | 27 Aug 2020 | Austin, Texas, United States | ||
Regenacy Pharmaceuticals | $30M | 25 Mar 2020 | Massachusetts, United States | ||
DTx Pharma | $10M | 06 Jan 2020 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Eubulus | $10M | 14 Oct 2021 | Jiaxing, Zhejiang, China | ||
Totient | $10M | 10 Sep 2020 | Cambridge, Massachusetts, United States | ||
Triumvira Immunologics | $55M | 27 Aug 2020 | Austin, Texas, United States | ||
Regenacy Pharmaceuticals | $30M | 25 Mar 2020 | Massachusetts, United States | ||
DTx Pharma | $10M | 06 Jan 2020 | San Diego, California, United States |